What antigens and components are contained in the Pentacel (DTaP‑IPV‑Hib) vaccine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 4, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pentacel Vaccine Components

Pentacel (DTaP-IPV/Hib) is a pentavalent combination vaccine containing diphtheria and tetanus toxoids, five acellular pertussis antigens, inactivated poliovirus types 1-3, and Haemophilus influenzae type b conjugate vaccine. 1

Specific Antigens and Components

Pertussis Component (Acellular)

Pentacel contains five pertussis antigens 1:

  • Inactivated pertussis toxin (PT) 1
  • Filamentous hemagglutinin (FHA) 1
  • Pertactin (PRN) 1
  • Fimbriae types 2 and 3 1

Poliovirus Component

  • Inactivated poliovirus types 1,2, and 3 - same strains as IPOL vaccine 1

Haemophilus influenzae type b Component

  • Hib capsular polysaccharide (PRP) conjugated to tetanus toxoid (PRP-T) 2, 3

Diphtheria and Tetanus Components

  • Diphtheria toxoid 1
  • Tetanus toxoid 1

Formulation Characteristics

Pentacel is a fully liquid formulation that requires reconstitution - the Hib component is lyophilized and must be reconstituted with the liquid DTaP-IPV component before administration 4, 5. This distinguishes it from some newer hexavalent vaccines that are fully liquid 1.

Clinical Context

Pentacel has been used extensively in Canada for over 10 years and was the first DTaP-based vaccine approved in the US that includes both poliovirus and Hib antigens 3. The vaccine demonstrates high immunogenicity across all component antigens, with seroprotection rates of 97-99% for anti-PRP antibodies and approximately 95% for other components 2, 5.

The safety profile shows low reactogenicity with fewer injection-site reactions compared to separately administered vaccines 2, 6. Studies demonstrate that DTaP-IPV/Hib combination vaccination results in significantly lower adverse event reporting rates (66.9/million doses) compared to separate administration of DTaP+IPV+Hib vaccines (637.8/million doses) 6.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.